National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Ofatumumab (Kesimpta®). HTA ID: 21008

Ofatumumab (Kesimpta®) is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.

 

NCPE Assessment Process Complete
Rapid review commissioned 15/03/2021
Rapid review completed 16/04/2021
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ofatumumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.